公开(公告)号：US20230303985A1

公开(公告)日：2023-09-28

申请号：US18046131

申请日：2022-10-12

申请人： The Trustees of Columbia University in the City of New York

发明人： Antonio IAVARONE ,  Anna LASORELLA ,  Raul RABADAN

IPC分类号： C12N9/12 ,  C07K14/71 ,  C07K14/47 ,  C12N9/16 ,  A61K38/17 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  G01N33/574 ,  A61K31/517 ,  C07K14/435 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/573

CPC分类号： C12N9/12 ,  C07K14/71 ,  C07K14/47 ,  C12N9/16 ,  C12Y301/03003 ,  A61K38/179 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/53 ,  G01N33/57484 ,  A61K31/517 ,  C07K14/435 ,  C07K14/4738 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/573 ,  C07K2319/00 ,  G01N2333/71 ,  C07K2317/76 ,  C12Y207/10001

摘要： The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

公开(公告)号：US10047131B2

公开(公告)日：2018-08-14

申请号：US15198540

申请日：2016-06-30

申请人： immatics biotechnologies GmbH

发明人： Andrea Mahr ,  Toni Weinschenk ,  Helen Hoerzer ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC分类号： A61K35/17 ,  C07K14/47 ,  C07K14/74 ,  A61K39/00 ,  C12N15/115 ,  C07K7/08 ,  C07K7/06 ,  C07K16/28 ,  C12N5/0783 ,  C07K16/30 ,  C12P21/02 ,  C12Q1/6881 ,  G01N33/569 ,  C07K14/82 ,  C07K16/32 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/705 ,  C07K16/18 ,  A61K38/00 ,  A61K35/12

CPC分类号： C07K14/4748 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4738 ,  C07K14/705 ,  C07K14/70539 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2833 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/30 ,  C12N2501/50 ,  C12N2501/998 ,  C12P21/02 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N33/57449 ,  G01N33/57492 ,  G01N2333/70539

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US09994845B2

公开(公告)日：2018-06-12

申请号：US15023869

申请日：2014-09-12

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.

发明人： David Sharp

IPC分类号： C12N15/11 ,  C12N15/113 ,  C07K14/47

CPC分类号： C12N15/113 ,  C07K14/4738 ,  C12N2310/14 ,  C12Y306/04004

摘要： Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.

公开(公告)号：US09982015B2

公开(公告)日：2018-05-29

申请号：US15192247

申请日：2016-06-24

申请人： University of South Carolina

发明人： Campbell McInnes ,  Padmavathy Nandha Premnath ,  Joshua K. Bolger

IPC分类号： A61K38/06 ,  C07K7/06 ,  C07K5/117 ,  A61K38/00

CPC分类号： C07K7/06 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  C07K5/0202 ,  C07K5/06095 ,  C07K5/06139 ,  C07K5/0821 ,  C07K5/101 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1024 ,  C07K14/4738

摘要： Structural and functional analysis of peptide inhibitor binding to the cyclin D and cyclin A groove has been investigated and used to design peptides that provide the basis for structure-activity relationships, have improved binding and have potential for development as chemical biology probes, as potential diagnostics and as therapeutics in the treatment of proliferative diseases including cancer and inflammation.

公开(公告)号：US20170246248A1

公开(公告)日：2017-08-31

申请号：US15586653

申请日：2017-05-04

申请人： APIM THERAPEUTICS AS

发明人： Marit Otterlei ,  Per Arne Aas ,  Emadoldin Feyzi

IPC分类号： A61K38/17 ,  A61K38/16 ,  A61K38/46 ,  A61K45/06

CPC分类号： A61K38/1709 ,  A61K38/00 ,  A61K38/16 ,  A61K38/46 ,  A61K45/06 ,  C07K14/00 ,  C07K14/4738 ,  C07K2319/10 ,  C12Y306/03044 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2800/56

摘要： Disclosed is A method of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy by administering an oligopeptidic compound to a subject in need thereof. The oligopeptidic compound is capable of interacting with proliferating cell nuclear antigen (PCNA) The compound comprises a PCNA interacting motif which is: which is: [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R] (SEQ ID NO. 28).The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence.

公开(公告)号：US09738695B2

公开(公告)日：2017-08-22

申请号：US15177206

申请日：2016-06-08

申请人： SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.

发明人： Liping Liu ,  Ru Bai

IPC分类号： A61K38/00 ,  C07K14/475 ,  A61P29/00 ,  C07K7/08 ,  C07K14/47 ,  C07K7/02

CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K7/02 ,  C07K7/08 ,  C07K14/4705 ,  C07K14/4733 ,  C07K14/4738

摘要： The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.

公开(公告)号：US09670252B2

公开(公告)日：2017-06-06

申请号：US14633153

申请日：2015-02-27

申请人： Viva Biotech (Shanghai) Ltd.

发明人： Jianhua Cai ,  Jian Shen ,  Fan Jiang ,  Na Li ,  Wentao Wei ,  Xiuhong Zeng ,  Xiaoyan Su ,  Min Han ,  Delin Ren ,  Chen Mao

IPC分类号： C07K14/705 ,  C07K14/00 ,  C07K14/72 ,  C07K14/435 ,  C07K14/47

CPC分类号： C07K14/001 ,  C07K14/43545 ,  C07K14/4703 ,  C07K14/4738 ,  C07K14/723 ,  C07K2319/00 ,  C07K2319/35

摘要： The present invention relates to fusion proteins for the expression of G-protein coupled receptor proteins (GPCR) with the fusion partners, as inserted fragments, from mammalian cells. The fusion partners are from a fragment of APJ protein (“the APJ protein fragment”) or a fragment with homology of more than 90% similarity to the APJ protein fragment; or a fragment of RGS16 protein (the “RGS16 protein fragment”) or a fragment with homology of more than 90% similarity to the RGS16 protein fragment; or the fragment of DNJ protein (the “DNJ protein fragment”) or a fragment with homology of more than 90% similarity to DNJ protein fragment. The fusion expression of GPCR with the above mentioned fusion partners can improve the protein yield and stability when purified from cells. Therefore, these fusion protein partners can be widely used for the study of GPCR proteins.

公开(公告)号：US09534030B2

公开(公告)日：2017-01-03

申请号：US13630862

申请日：2012-09-28

申请人： SURVAC APS

发明人： Eivind Per Thor Straten ,  Mads Hald Andersen

IPC分类号： A61K39/002 ,  A61K47/00 ,  A61K47/48 ,  A61K39/39 ,  G01N33/574 ,  C07K14/47 ,  A61K39/00 ,  A61K38/00

CPC分类号： C07K14/4747 ,  A61K38/00 ,  A61K39/0011 ,  A61K39/002 ,  A61K39/39 ,  A61K47/00 ,  A61K47/51 ,  A61K2039/5154 ,  A61K2039/5158 ,  C07K14/4738 ,  G01N33/574 ,  G01N33/57484

摘要： MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.

摘要翻译： 衍生自肿瘤相关抗原的MHC I类限制性肽，存活蛋白，该肽能够以高亲和力结合至I类HLA分子，能够在癌症患者的PBL群体中引发产生INF-γ的细胞，并具有能力 原位检测肿瘤组织中的细胞毒性T细胞，包含该肽的治疗和诊断组合物及其用途。

公开(公告)号：US20160369258A1

公开(公告)日：2016-12-22

申请号：US15122346

申请日：2015-03-11

申请人： UNIVERSITY OF WASHINGTON

发明人： Nancy Maizels ,  Quy Le

IPC分类号： C12N9/78 ,  C12P21/00 ,  C12N15/85 ,  C07K14/47 ,  C07K16/00

CPC分类号： C12N9/78 ,  C07K14/4738 ,  C07K16/00 ,  C07K2317/14 ,  C07K2319/00 ,  C12N15/63 ,  C12N15/85 ,  C12P21/005 ,  C12Y305/04 ,  C12Y305/04001

摘要： The present invention relates generally to mutagenesis of target genes that enhances the natural mutagenic capabilities of adaptive immune cells by providing a chimeric construct that exploits the ability of molecules such as AID to stimulate diversification and the ability of a second molecule to restrict nuclear activity of the molecules and/or protect cell viability. The invention provides a method for stimulating diversification in expressed genes, such as antibody genes, using polypeptides whose nuclear activity is restricted to specific phases of the cell cycle. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity, or for developing T cells for immunotherapy. The invention provides an improved means of developing a repertoire of variant immunoglobulins and other polypeptides.

摘要翻译： 本发明一般涉及通过提供嵌合构建体来增强适应性免疫细胞的天然诱变能力的靶基因的突变，所述嵌合构建体利用诸如AID之类的分子刺激多样化的能力以及第二分子限制第二分子的核活性的能力 分子和/或保护细胞活力。 本发明提供了一种利用其活性限于细胞周期特定阶段的多肽刺激表达基因如抗体基因多样化的方法。 该方法可以与选择相结合以鉴定产生例如高亲和性或特异性的抗体或用于开发用于免疫治疗的T细胞的B细胞克隆。 本发明提供了开发变体免疫球蛋白和其他多肽的所有组成成分的改进方法。

公开(公告)号：US09512193B2

公开(公告)日：2016-12-06

申请号：US14615224

申请日：2015-02-05

申请人： Samsung Electronics Co., Ltd.

发明人： Jung-Hoon Lee ,  Jae Il Lee ,  Eunji Kang ,  Jungmin Lee

IPC分类号： C07K14/47 ,  A61K38/00

CPC分类号： C07K14/4738 ,  A61K38/00 ,  C07K14/4703

摘要： A p15 protein variant; a polynucleotide encoding the p15 protein variant; a method for preparing the p15 protein variant; a pharmaceutical composition comprising the p15 protein variant; and a method for preventing and/or treating cancer comprising administering the p15 protein variant to a subject.

摘要翻译： p15蛋白质变体; 编码p15蛋白变体的多核苷酸; 制备p15蛋白变体的方法; 包含该p15蛋白质变体的药物组合物; 以及用于预防和/或治疗癌症的方法，其包括将p15蛋白质变体施用于受试者。